新的CAR Treg疗法将小鼠的动脉斑块减少了70%,为治疗人类心脏病提供了潜力。 A new CAR Treg therapy reduced artery plaque by 70% in mice, offering potential for treating heart disease in humans.

一项新的临床预科研究表明,为针对动脉中的炎症而设计的经修改的CAR T细胞疗法,在容易发生天体硬化症的小鼠中,将斑块减少了70%。 A new preclinical study shows that a modified CAR T cell therapy, designed to target inflammation in arteries, reduced plaque by 70% in mice prone to atherosclerosis. 与抗癌的CAR T细胞不同,这个版本称为CAR Treg-Calm对氧化LDL的有害免疫反应,LDL是心脏病的主要致病因素。 Unlike cancer-fighting CAR T cells, this version—called CAR Treg—calms harmful immune responses to oxidized LDL, a key driver of heart disease. 这种方法使用病人自己的细胞,提供了一种可能的新治疗方法,治疗无神体硬化症,这是心脏病发作和中风的主要原因,对于尽管进行目前的治疗仍然处于危险之中的人来说尤其如此。 The approach, which uses a patient’s own cells, offers a potential new treatment for atherosclerosis, the leading cause of heart attacks and strokes, especially for those still at risk despite current therapies. 为了确认安全和有效性,需要进行人类试验。 Human trials are needed to confirm safety and effectiveness.